Romiplostim injection for treatment-resistant ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with diagnosed primary ITP (immune system attacking your own platelets)
- Failed previous oral platelet-boosting drugs (eltrombopag, hetrombopag, or avatrombopag) due to poor response, loss of response, or side effects
- Platelet count below 30×10⁹/L confirmed by at least two blood tests at least 5 days apart
- Able to receive weekly injections under the skin and follow all study visits and procedures
- No previous romiplostim treatment, recent spleen removal, or blood clots; no severe liver, kidney, or heart disease
- For women: negative pregnancy test and agreement to use birth control during the study and 3 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
This trial tests the safety and effectiveness of a drug called romiplostim for children ages 1 to 18 who have chronic ITP (a condition where the immune system destroys platelets, causing low platelet counts and bleeding risk). It may be an option for children whose ITP has not improved with or who cannot tolerate other treatments like steroids, IVIG, or eltrombopag.
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
This study tests a combination of three treatments—steroids, IVIG, and romiplostim (Nplate)—for adults with severe, newly diagnosed ITP that hasn't responded well to standard therapy. The goal is to see if this triple therapy can quickly raise platelet counts and stop bleeding.
Hear when a new Immune (Idiopathic) Thrombocytopenic Purpura (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.